Docoh
Loading...

HGEN Humanigen

News

From Benzinga Pro
20 Stocks Moving in Monday's Pre-Market Session
10 Jan 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Bone Biologics Corporation (NASDAQ: BBLG) rose 32.1% to $4.53 in pre-market trading.
Humanigen Aligns With FDA On Potential Registration Phase 3 Study For Lenzilumab With CAR-T
10 Jan 22
News, FDA
Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ today outlined the next
Stocks That Hit 52-Week Lows On Friday
7 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Before 10 am on Friday, 110 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
6 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Thursday, 615 stocks hit new 52-week lows.
Stocks Hitting New 52-Week Lows Today
3 Jan 22
News, Intraday Update, Markets, Movers, Trading Ideas
On Monday morning, 60 companies achieved new lows for the year.
Humanigen Announced Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels
3 Jan 22
News, Penny Stocks
Humanigen, Inc.
65 Biggest Movers From Yesterday
21 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index.
After FDA Rejection, Humanigen's COVID-19 Drug Hopeful Sees Some Light Of Good News
2 Dec 21
Biotech, Long Ideas, News, Health Care, Small Cap, Movers, Trading Ideas, General
Humanigen Inc (NASDAQ: HGEN) announced that The Lancet Respiratory Medicine
27 Stocks Moving in Thursday's Pre-Market Session
2 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Phunware, Inc. (NASDAQ: PHUN) rose 25.8% to $4.09 in pre-market trading after surging around 12% on Wednesday.
20 Stocks Moving in Monday's Pre-Market Session
29 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 85.6% to $3.88 in pre-market trading after jumping 14% on Friday. Petros Pharmaceuticals recently said Q3 sales results were down year over year.
Humanigen Announces Abstracts Accepted For The British Thoracic Society Winter Meeting 2021
22 Nov 21
News
Abstract #S48 describes top-line results from the Humanigen Phase 3 LIVE-AIR study in hospitalized COVID-19 patients, which reveal a 54% relative improvement in the likelihood of survival without invasive
Humanigen Q3 Sales $1.04M
12 Nov 21
Earnings, News
Humanigen (NASDAQ:HGEN) reported $1.04 million in sales this quarter.
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
11 Nov 21
Biotech, Earnings, News, FDA, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours:
Humanigen Announces Clinical Trial Collaboration To Evaluate Lenzilumab In Acute Graft Versus Host Disease
11 Nov 21
News, Contracts
Humanigen is supporting the University of Birmingham to conduct a Phase 2/3, potentially registrational, clinical trial at IMPACT stem cell transplant centers across the United Kingdom The "Risk Adapted Therapy
12 Health Care Stocks Moving In Monday's Pre-Market Session
8 Nov 21
Pre-Market Outlook, Markets, Movers

Press releases

From Benzinga Pro
Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab
18 Jan 22
Press Releases
Lenzilumab plus standard of care (SOC), resulted in an estimated cost savings of $13,190 per patient (net savings of $3,190, after an assumed price of $10,000 for lenzilumab) in those receiving remdesivir with baseline
Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T
10 Jan 22
Press Releases
FDA Type C meeting and advice creates alignment on registration pathway for Phase 3 clinical development of lenzilumab for the prevention of CAR-T therapy related toxicities including Immune Effector Cell-Associated
Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved
5 Jan 22
Press Releases
Top-line data from ACTIV-5/BET-B expected to be announced late in the first quarter or early in the second quarter of 2022 ACTIV-5/BET-B results to be shared with regulatory authorities in the US, UK, and EU as part
Humanigen to Present at Investor Conferences January 7 and 13, 2022
4 Jan 22
Press Releases
Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that Cameron Durrant, chairman and
Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels
3 Jan 22
Press Releases
Multi-variate analysis of LIVE-AIR Phase 3 data demonstrates that elevated baseline C-Reactive Protein ("CRP") is the most predictive feature for progression to invasive mechanical ventilation ("IMV") or death and may
Humanigen Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference in January 2022
15 Dec 21
Press Releases
Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that Cameron Durrant, Chairman &
Thinking about buying stock in Phunware, Omeros Corp, Humanigen, Spirit AeroSystems, or Arbutus Biopharma?
2 Dec 21
Opinion, Press Releases
NEW YORK, Dec. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PHUN, OMER, HGEN, SPR, and ABUS.
Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update
1 Dec 21
Press Releases
Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that it will host a conference call
The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results
1 Dec 21
Press Releases
Lenzilumab is a variant-agnostic therapeutic that targets the dysregulated host immune response, an approach which may be of greater value than targeting the virus in hospitalized patients1 Per the paper, the
Humanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021
22 Nov 21
Press Releases
Abstract #S48 describes top-line results from the Humanigen Phase 3 LIVE-AIR study in hospitalized COVID-19 patients, which reveal a 54% relative improvement in the likelihood of survival without invasive mechanical
Humanigen Announces Revised Time for Presentation at Jefferies London Healthcare Conference
16 Nov 21
Press Releases
Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that its presentation time at the
Humanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate Update
12 Nov 21
Press Releases
Humanigen, Inc. (NASDAQ:HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‛cytokine storm' with its lead drug candidate, lenzilumab, today
Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host Disease
11 Nov 21
Press Releases
Humanigen is supporting the University of Birmingham to conduct a Phase 2/3, potentially registrational, clinical trial at IMPACT stem cell transplant centers across the United Kingdom The "Risk Adapted Therapy in
Humanigen Announces Release of Abstracts at ASH
5 Nov 21
Press Releases
Abstract #2777 describes preclinical models that demonstrate GM-CSF neutralization with lenzilumab improves CAR-T cell proliferation, but blocking the GM-CSFα receptor may inhibit CAR-T cell proliferation Abstract
Humanigen Announces Participation and Presentation at Multiple Conferences in November
2 Nov 21
Press Releases
Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that management will present and